Trial tests new drug duo against Tough-to-Treat cancer mutation

NCT ID NCT07441174

Summary

This study is testing a new combination of two drugs, IN10018 and RNK08954, for people with advanced solid tumors that have a specific genetic change called KRASG12D. The main goals are to find a safe and effective dose and to see if the treatment can shrink tumors. The study is open to adults with certain advanced cancers, like pancreatic cancer, who have tried standard treatments that didn't work or aren't available.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Affiliated Drum Tower Hospital, Medical School of Nanjing University

    NOT_YET_RECRUITING

    Nanjing, Jiangsu, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Cancer Hospital Chinese Academy of Medical Sciences

    NOT_YET_RECRUITING

    Beijing, Beijing Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Fujian Cancer Hospital

    NOT_YET_RECRUITING

    Fuzhou, Fujian, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hunan Cancer Hospital

    NOT_YET_RECRUITING

    Changsha, Hunan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Jiangsu Province Hospital

    NOT_YET_RECRUITING

    Nanjing, Jiangsu, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    NOT_YET_RECRUITING

    Shanghai, Shanghai Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shandong Cancer Hospital

    NOT_YET_RECRUITING

    Jinan, Shandong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    NOT_YET_RECRUITING

    Guangzhou, Guangdong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of China Medical University

    NOT_YET_RECRUITING

    Shengyang, Liaoning, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Henan University of Science and Technology

    NOT_YET_RECRUITING

    Luoyang, He, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Wenzhou Medical University

    NOT_YET_RECRUITING

    Wenzhou, Zhejiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Xi'an Jiaotong University

    NOT_YET_RECRUITING

    Xi’an, Shanxi, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Zhengzhou University

    NOT_YET_RECRUITING

    Zhengzhou, Henan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310005

    RECRUITING

    Hangzhou, Zhejiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.